Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017

  • ID: 4327564
  • Report
  • 1296 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Johnson & Johnson
  • Mycenax Biotech Inc
  • Plexxikon Inc
  • MORE
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 16, 88, 82, 3, 75, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 12, 5 and 11 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Johnson & Johnson
  • Mycenax Biotech Inc
  • Plexxikon Inc
  • MORE
Introduction

Kidney Cancer (Renal Cell Cancer) - Overview

Kidney Cancer (Renal Cell Cancer) - Therapeutics Development

Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment

Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development

Kidney Cancer (Renal Cell Cancer) - Drug Profiles

Kidney Cancer (Renal Cell Cancer) - Dormant Projects

Kidney Cancer (Renal Cell Cancer) - Discontinued Products

Kidney Cancer (Renal Cell Cancer) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Companies, H1 2017 (Contd..3), H1

Number of Products under Development by Companies, H1 2017 (Contd..4), H1

Number of Products under Development by Companies, H1 2017 (Contd..5), H1

Number of Products under Development by Companies, H1 2017 (Contd..6), H1

Number of Products under Development by Companies, H1 2017 (Contd..7), H1

Number of Products under Development by Companies, H1 2017 (Contd..8), H1

Number of Products under Development by Companies, H1 2017 (Contd..9), H1

Number of Products under Development by Universities/Institutes, H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Companies, H1 2017 (Contd..4), H1

Products under Development by Companies, H1 2017 (Contd..5), H1

Products under Development by Companies, H1 2017 (Contd..6), H1

Products under Development by Companies, H1 2017 (Contd..7), H1

Products under Development by Companies, H1 2017 (Contd..8), H1

Products under Development by Companies, H1 2017 (Contd..9), H1

Products under Development by Companies, H1 2017 (Contd..10), H1

Products under Development by Companies, H1 2017 (Contd..11), H1

Products under Development by Companies, H1 2017 (Contd..12), H1

Products under Development by Companies, H1 2017 (Contd..13), H1

Products under Development by Companies, H1 2017 (Contd..14), H1

Products under Development by Companies, H1 2017 (Contd..15), H1

Products under Development by Companies, H1 2017 (Contd..16), H1

Products under Development by Companies, H1 2017 (Contd..17), H1

Products under Development by Companies, H1 2017 (Contd..18), H1

Products under Development by Companies, H1 2017 (Contd..19), H1

Products under Development by Universities/Institutes, H1

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1 2017 (Contd..2), H1

Number of Products by Stage and Target, H1 2017 (Contd..3), H1

Number of Products by Stage and Target, H1 2017 (Contd..4), H1

Number of Products by Stage and Target, H1 2017 (Contd..5), H1

Number of Products by Stage and Target, H1 2017 (Contd..6), H1

Number of Products by Stage and Target, H1 2017 (Contd..7), H1

Number of Products by Stage and Target, H1 2017 (Contd..8), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Actuate Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Aduro BioTech Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics LLC, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Alkermes Plc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corp, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Apac Biotech Pvt Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Aphios Corp, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by ARMO Biosciences Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc, H1

ney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by BeiGene (Beijing) Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Berg LLC, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Biocad, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by CBT Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corp, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Celyad SA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Cleave Biosciences Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by COARE Biotechnology Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Gene Techno Science Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Genentech Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Hemispherx Biopharma Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by HitGen LTD, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison China MediTech Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Ignyta Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomet Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corp, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Innovation Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Inovio Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Inspyr Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Kite Pharma Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Konruns Pharmaceutical Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Lead Discovery Center GmbH, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Lidds AB, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Lion Biotechnologies Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Mantis Therapeutics BV, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by MaxiVAX SA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune LLC, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Medinet Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Merrimack Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Molecular Partners AG, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Moleculin Biotech Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Mount Tam Biotechnologies Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by NantKwest Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by NBE-Therapeutics AG, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corp, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by NovaTarg Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corp, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by OncBioMune Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncogenex Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoTherapy Science Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncovir Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharma Mar SA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Plexxikon Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio SL, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Richter Gedeon Nyrt, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita SA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Sillajen Biotherapeutics, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Synthon Holdings BV, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Systimmune Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Taris Biomedical LLC, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Tocagen Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Tolero Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by UroGen Pharmaceuticals Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Valeant Pharmaceuticals International Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Vault Pharma Inc, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by ViiV Healthcare Ltd, H1

Kidney Cancer (Renal Cell Cancer) - Pipeline by X4 Pharmaceuticals Inc, H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..1), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..2), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..3), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..4), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..5), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..6), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..7), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..8), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..9), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..10), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..11), H1

Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..12), H1

Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1

Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1 2017 (Contd..1), H1

Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1 2017 (Contd..2), H1

List of Figures

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • AbbVie Inc
  • Actuate Therapeutics Inc
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech Inc
  • Advanced Cancer Therapeutics LLC
  • Advenchen Laboratories LLC
  • Affitech A/S
  • Alethia Biotherapeutics Inc
  • Alkermes Plc
  • Altor BioScience Corp
  • Ambrx Inc
  • Amgen Inc
  • Ampio Pharmaceuticals Inc
  • Apac Biotech Pvt Ltd
  • Apcure SAS
  • APEIRON Biologics AG
  • Aphios Corp
  • arGEN-X BV
  • Argos Therapeutics Inc
  • ARMO Biosciences Inc
  • ArQule Inc
  • Arrowhead Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene (Beijing) Co Ltd
  • Berg LLC
  • Bio-Cancer Treatment International Ltd
  • Biocad
  • Bionomics Ltd
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Company
  • Calithera Biosciences Inc
  • CASI Pharmaceuticals Inc
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellular Biomedicine Group Inc
  • Celyad SA
  • Chipscreen Biosciences Ltd
  • Cleave Biosciences Inc
  • COARE Biotechnology Inc
  • Coherus BioSciences Inc
  • Corvus Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Ecrins Therapeutics SAS
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Genor BioPharma Co Ltd
  • GlaxoSmithKline Plc
  • Glycotope GmbH
  • Hemispherx Biopharma Inc
  • HitGen LTD
  • Horizon Pharma Plc
  • Hutchison China MediTech Ltd
  • Ignyta Inc
  • Immune Design Corp
  • Immune Pharmaceuticals Inc
  • Immunicum AB
  • ImmunoFrontier Inc
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immunomet Therapeutics Inc
  • Incyte Corp
  • Innate Immunotherapeutics Ltd
  • Innovation Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Johnson & Johnson
  • KAHR medical Ltd
  • Karyopharm Therapeutics Inc
  • KineMed Inc
  • Kite Pharma Inc
  • Komipharm International Co Ltd
  • Konruns Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Lead Discovery Center GmbH
  • Lidds AB
  • Lion Biotechnologies Inc
  • Mabion SA
  • MacroGenics Inc
  • Mantis Therapeutics BV
  • MaxiVAX SA
  • MedImmune LLC
  • Medinet Co Ltd
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Millennium Pharmaceuticals Inc
  • Mirati Therapeutics Inc
  • Molecular Partners AG
  • Moleculin Biotech Inc
  • Monopar Therapeutics LLC
  • Mount Tam Biotechnologies Inc
  • Mycenax Biotech Inc
  • NanoSmart Pharmaceuticals Inc
  • NantKwest Inc
  • NBE-Therapeutics AG
  • Nektar Therapeutics
  • NewLink Genetics Corp
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Omeros Corp
  • OncBioMune Pharmaceuticals Inc
  • Oncobiologics Inc
  • Oncogenex Pharmaceuticals Inc
  • Oncolys BioPharma Inc
  • OncoMax
  • OncoTherapy Science Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Peloton Therapeutics Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Pharmicell Co Ltd
  • Pivotal BioSciences Inc
  • Plexxikon Inc
  • Prima BioMed Ltd
  • PsiOxus Therapeutics Ltd
  • Recombio SL
  • Rexahn Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Sanofi
  • Selvita SA
  • Sevion Therapeutics Inc
  • Sillajen Biotherapeutics
  • Sorrento Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Syndax Pharmaceuticals Inc
  • Synthon Holdings BV
  • Systimmune Inc
  • Taiwan Liposome Company Ltd
  • Taris Biomedical LLC
  • TC BioPharm Ltd
  • Tocagen Inc
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • TVAX Biomedical Inc
  • Tyrogenex Inc
  • UroGen Pharmaceuticals Ltd
  • Valeant Pharmaceuticals International Inc
  • Vascular Biogenics Ltd
  • Vault Pharma Inc
  • Vaxeal Holding SA
  • ViiV Healthcare Ltd
  • X4 Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll